347 related articles for article (PubMed ID: 19017737)
41. Mortality in COPD: Role of comorbidities.
Sin DD; Anthonisen NR; Soriano JB; Agusti AG
Eur Respir J; 2006 Dec; 28(6):1245-57. PubMed ID: 17138679
[TBL] [Abstract][Full Text] [Related]
42. Endothelial function in patients with chronic obstructive pulmonary disease: a systematic review of studies using flow mediated dilatation.
Vaes AW; Spruit MA; Theunis J; Goswami N; Vanfleteren LE; Franssen FME; Wouters EFM; De Boever P
Expert Rev Respir Med; 2017 Dec; 11(12):1021-1031. PubMed ID: 28978239
[TBL] [Abstract][Full Text] [Related]
43. COPD in chronic heart failure: less common than previously thought?
Minasian AG; van den Elshout FJ; Dekhuijzen PN; Vos PJ; Willems FF; van den Bergh PJ; Heijdra YF
Heart Lung; 2013; 42(5):365-71. PubMed ID: 23998385
[TBL] [Abstract][Full Text] [Related]
44. Platelet activation and cardiovascular comorbidities in patients with chronic obstructive pulmonary disease.
Malerba M; Olivini A; Radaeli A; Ricciardolo FL; Clini E
Curr Med Res Opin; 2016 May; 32(5):885-91. PubMed ID: 26824631
[TBL] [Abstract][Full Text] [Related]
45. The speed of blood pressure fluctuations in patients with chronic obstructive pulmonary disease.
van Gestel AJ; Clarenbach CF; Stöwhas AC; Rossi VA; Sievi NA; Camen G; Kohler M
Heart Lung Circ; 2014 Mar; 23(3):280-6. PubMed ID: 24080024
[TBL] [Abstract][Full Text] [Related]
46. Aerobic exercise training does not alter vascular structure and function in chronic obstructive pulmonary disease.
Gelinas JC; Lewis NC; Harper MI; Melzer B; Agar G; Rolf JD; Eves ND
Exp Physiol; 2017 Nov; 102(11):1548-1560. PubMed ID: 28857336
[TBL] [Abstract][Full Text] [Related]
47. Systemic effects of chronic obstructive pulmonary disease.
Agustí AG; Noguera A; Sauleda J; Sala E; Pons J; Busquets X
Eur Respir J; 2003 Feb; 21(2):347-60. PubMed ID: 12608452
[TBL] [Abstract][Full Text] [Related]
48. Risk of mortality from cardiovascular and respiratory causes in patients with chronic obstructive pulmonary disease submitted to follow-up after lung resection for non-small cell lung cancer.
Volpino P; Cangemi R; Fiori E; Cangemi B; De Cesare A; Corsi N; Di Cello T; Cangemi V
J Cardiovasc Surg (Torino); 2007 Jun; 48(3):375-83. PubMed ID: 17505444
[TBL] [Abstract][Full Text] [Related]
49. [Pleiotropic Effects of Rosuvastatin in Chronic Obstructive Pulmonary Disease Patients With High Cardiovascular Risk].
Samorukova EI; Adasheva TV; Zadionchenko VS; Rosliakova GA
Kardiologiia; 2015; 55(7):32-7. PubMed ID: 26688923
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of Markers of Inflammation and Oxidative Stress in COPD Patients with or without Cardiovascular Comorbidities.
Kaźmierczak M; Ciebiada M; Pękala-Wojciechowska A; Pawłowski M; Nielepkowicz-Goździńska A; Antczak A
Heart Lung Circ; 2015 Aug; 24(8):817-23. PubMed ID: 25797323
[TBL] [Abstract][Full Text] [Related]
51. [Comorbidities of COPD].
Watz H; Magnussen H
Internist (Berl); 2006 Sep; 47(9):895-6, 898-900. PubMed ID: 16821069
[TBL] [Abstract][Full Text] [Related]
52. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].
Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Rousseau R;
BMC Pulm Med; 2006 Feb; 6():3. PubMed ID: 16460562
[TBL] [Abstract][Full Text] [Related]
53. [Consequences of atmospheric pollution fluctuations in patients with COPD].
Amiot N; Tillon J; Viacroze C; Aouine H; Muir JF
Rev Mal Respir; 2010 Oct; 27(8):907-12. PubMed ID: 20965405
[TBL] [Abstract][Full Text] [Related]
54. [The effects of hypoxia on initiation and progression of cardiovascular disease in patients with chronic obstructive pulmonary disease].
Lyzogub VH; Savchenko OV; Zaval's'ka TV; Dykukha IS; Tyravs'ka IuV
Lik Sprava; 2012; (5):27-34. PubMed ID: 23534269
[TBL] [Abstract][Full Text] [Related]
55. Chronic obstructive pulmonary disease: linking outcomes and pathobiology of disease modification.
Rennard SI
Proc Am Thorac Soc; 2006 May; 3(3):276-80. PubMed ID: 16636098
[TBL] [Abstract][Full Text] [Related]
56. Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: protocol of a randomised controlled proof-of-concept trial (APPLE COPD-ICON 2).
Kunadian V; Chan D; Ali H; Wilkinson N; Howe N; McColl E; Thornton J; von Wilamowitz-Moellendorff A; Holstein EM; Burns G; Fisher A; Stocken D; De Soyza A;
BMJ Open; 2018 May; 8(5):e020713. PubMed ID: 29804061
[TBL] [Abstract][Full Text] [Related]
57. Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases.
Cazzola M; Calzetta L; Rinaldi B; Page C; Rosano G; Rogliani P; Matera MG
Drugs; 2017 May; 77(7):721-732. PubMed ID: 28349353
[TBL] [Abstract][Full Text] [Related]
58. The importance of cardiovascular disease for mortality in patients with COPD: a prognostic cohort study.
Zhang J; Rutten FH; Cramer MJ; Lammers JW; Zuithoff NP; Hoes AW
Fam Pract; 2011 Oct; 28(5):474-81. PubMed ID: 21602286
[TBL] [Abstract][Full Text] [Related]
59. 8-Isoprostane as a marker of oxidative stress in nonsymptomatic cigarette smokers and COPD.
Kinnula VL; Ilumets H; Myllärniemi M; Sovijärvi A; Rytilä P
Eur Respir J; 2007 Jan; 29(1):51-5. PubMed ID: 17050565
[TBL] [Abstract][Full Text] [Related]
60. Low-grade adipose tissue inflammation in patients with mild-to-moderate chronic obstructive pulmonary disease.
van den Borst B; Gosker HR; Wesseling G; de Jager W; Hellwig VA; Snepvangers FJ; Schols AM
Am J Clin Nutr; 2011 Dec; 94(6):1504-12. PubMed ID: 22071714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
